

| Section/Topic                | Item | Checklist Item  | Page Number/Location  |
|------------------------------|------|---|---|
| <b>Title and abstract</b>    |      |   |   |
| Title                        | 1    | Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.  | Page 1/ Title Page  |
| Abstract                     | 2    | Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.   | Page 3-4/ Abstract  |
| <b>Introduction</b>          |      |   |   |
| Background and objectives    | 3a   | Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.      | Page 5-6/ Introduction  |
|                              | 3b   | Specify the objectives, including whether the study describes the development or validation of the model or both.   | Page 6-7/ Introduction  |
| <b>Methods</b>               |      |   |   |
| Source of data               | 4a   | Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.                               | Page 8-9/ Methods – Study design and subjects                       |
|                              | 4b   | Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.  | Page 8-9/ Methods – Study design and subjects                       |
| Participants                 | 5a   | Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.  | Page 8-9/ Methods – Study design and subjects                       |
|                              | 5b   | Describe eligibility criteria for participants.   | Page 8-9/ Methods – Study design and subjects                       |
|                              | 5c   | Give details of treatments received, if relevant.   | Not applicable  |
| Outcome                      | 6a   | Clearly define the outcome that is predicted by the prediction model, including how and when assessed.  | Page 9/ Data Collection and Definitions                             |
|                              | 6b   | Report any actions to blind assessment of the outcome to be predicted.  | Not applicable  |
| Predictors                   | 7a   | Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.   | Page 9/ Data Collection and Definitions                             |
|                              | 7b   | Report any actions to blind assessment of predictors for the outcome and other predictors.  | Not applicable  |
| Sample size                  | 8    | Explain how the study size was arrived at.  | Page 8/ Methods – Study design and subjects                         |
| Missing data                 | 9    | Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.  | Page10/ Methods – Data preprocessing and Machine Learning Modelling |
| Statistical analysis methods | 10a  | Describe how predictors were handled in the analyses.   | Page10/ Methods – Data preprocessing and Machine Learning Modelling |
|                              | 10b  | Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.   | Page10/ Methods – Data preprocessing and Machine Learning Modelling |
|                              | 10d  | Specify all measures used to assess model performance and, if relevant, to compare multiple models.   | Page11 / Methods – Performance evaluation and interpretation        |
| Risk groups                  | 11   | Provide details on how risk groups were created, if done.   | Not applicable  |
| <b>Results</b>               |      |   |   |
| Participants                 | 13a  | Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful. | Page 12-16/ Results   |
|                              | 13b  | Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.    | Page 12-16/ Results   |
| Model development            | 14a  | Specify the number of participants and outcome events in each analysis.   | Page 12-16/ Results   |
|                              | 14b  | If done, report the unadjusted association between each candidate predictor and outcome.  | Not applicable  |
| Model specification          | 15a  | Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).                           | Not applicable  |
|                              | 15b  | Explain how to use the prediction model.  | Page 16-22/ Results   |
| Model performance            | 16   | Report performance measures (with CIs) for the prediction model.  | Page 16-22/ Results   |
| <b>Discussion</b>            |      |   |   |

## TRIPOD Checklist: Prediction Model Development

|                           |     |  |                           |
|---------------------------|-----|--|---------------------------|
| Limitations               | 18  | Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).                                   | Page 27-28/ Discussion    |
| Interpretation            | 19b | Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence. | Page 22-27/ Discussion    |
| Implications              | 20  | Discuss the potential clinical use of the model and implications for future research.  | Page 22-28/ Discussion    |
| <b>Other information</b>  |     |  |                           |
| Supplementary information | 21  | Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.                      | Not applicable            |
| Funding                   | 22  | Give the source of funding and the role of the funders for the present study.  | Page 29/ Acknowledgements |

We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.